Compare · DGX vs ILMN
DGX vs ILMN
Side-by-side comparison of Quest Diagnostics Incorporated (DGX) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DGX and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $24.56B, about 1.1x DGX ($22.17B).
- Over the past year, DGX is up 13.9% and ILMN is up 91.0% - ILMN leads by 77.1 points.
- ILMN has been more active in the news (21 items in the past 4 weeks vs 13 for DGX).
- Both have 25 recent analyst ratings on file.
- Company
- Quest Diagnostics Incorporated
- Illumina Inc.
- Price
- $200.30+2.06%
- $162.28-3.39%
- Market cap
- $22.17B
- $24.56B
- 1M return
- +5.90%
- +13.81%
- 1Y return
- +13.90%
- +90.96%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2000
- News (4w)
- 13
- 21
- Recent ratings
- 25
- 25
Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest DGX
- CEO and President Davis J. E. sold $1,941,400 worth of shares (10,000 units at $194.14) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 132,423 units (SEC Form 4)
- Director Carter Robert B was granted 1,142 shares, increasing direct ownership by 42% to 3,853 units (SEC Form 4)
- Director Gregg Vicky B was granted 1,142 shares, increasing direct ownership by 7% to 18,314 units (SEC Form 4)
- Director Main Timothy L was granted 1,142 shares, increasing direct ownership by 4% to 27,439 units (SEC Form 4)
- Director Diaz Luis was granted 1,142 shares, increasing direct ownership by 28% to 5,196 units (SEC Form 4)
- Director Wentworth Timothy C was granted 1,142 shares, increasing direct ownership by 529% to 1,358 units (SEC Form 4)
- Director Doi Tracey was granted 1,142 shares, increasing direct ownership by 17% to 7,748 units (SEC Form 4)
- Director Ring Timothy M was granted 1,142 shares, increasing direct ownership by 4% to 31,140 units (SEC Form 4)
- Director Lassiter Wright Iii was granted 1,142 shares, increasing direct ownership by 12% to 10,317 units (SEC Form 4)
- Director Morrison Denise M was granted 1,142 shares, increasing direct ownership by 11% to 11,929 units (SEC Form 4)
Latest ILMN
- SVP, Chief People Officer Leckman Patricia sold $127,068 worth of shares (784 units at $162.08), decreasing direct ownership by 3% to 22,042 units (SEC Form 4)
- Director Meister Keith A. sold $107,042,631 worth of shares (669,596 units at $159.86) (SEC Form 4)
- Chief Legal Officer Davies Scott M sold $98,400 worth of shares (615 units at $160.00), decreasing direct ownership by 3% to 21,568 units (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D sold $305,150 worth of shares (2,000 units at $152.57), decreasing direct ownership by 12% to 14,446 units (SEC Form 4)
- Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
- Amendment: SEC Form 4 filed by Director Meister Keith A.
- Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
- Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
- Illumina Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director King David P was granted 2,072 shares (SEC Form 4)